Advances in understanding pituitary tumors

Area of Science:

• Endocrinology
• Neurosurgery
• Oncology

Background:

• Pituitary tumors are increasingly diagnosed due to advanced neuroimaging.
• Most pituitary tumors are benign adenomas, while carcinomas are rare.
• Genetic and epigenetic factors are crucial for understanding pituitary tumor development.

Purpose of the Study:

• To review the current understanding of pituitary tumors, including their diagnosis, classification, and treatment.
• To highlight the role of genetic abnormalities in pituitary tumorigenesis.
• To discuss the evolving therapeutic landscape for pituitary tumors.

Main Methods:

• Literature review of pituitary tumor epidemiology, pathology, and clinical management.
• Analysis of diagnostic techniques, including neuroimaging.
• Summary of current and emerging treatment modalities, encompassing surgical, radiological, and pharmaceutical interventions.

Main Results:

• Pituitary tumors affect approximately 16.7% of the population, predominantly as benign adenomas.
• Macroadenomas can cause significant complications like visual disturbances and hypopituitarism.
• Functional classification reveals non-functioning adenomas (33-50%), prolactinomas (25-41%), acromegaly (10-15%), and Cushing's disease (10%).

Conclusions:

• Surgical resection (transsphenoidal, adenomectomy) and radiosurgery are primary treatments, except for prolactinomas managed with medication.
• Pharmaceutical options, including dopamine agonists and somatostatin analogues, are vital, with newer agents like temozolomide showing promise for aggressive tumors.
• Ongoing research into genetic and epigenetic factors is paving the way for novel targeted therapies.